Looking to sell Synthego stock or options?
Synthego has developed a precision genome engineering platform to expedite and enhance the process of drug discovery research. The platform, which integrates informatics and machine learning, introduces precision and automation to genome engineering. This innovation allows genetic engineers and healthcare practitioners to carry out research swiftly, cost-effectively, and with consistent outcomes for all scientists involved.
Perceptive Advisors, Declaration Partners, Moore Strategic Ventures, Menlo Ventures, ZhenFund, AAF Management, Wellington Management, 8VC, Pagoda Investment, Elements Capital Partners, GigaFund, AME Cloud Ventures, Tony Huang, SciFi VC, Moshen Chan, Chimera Capital, Intel Capital, Revelation Partners, Open Field Capital, Level One Fund, OS Fund, RA Capital Management, Founders Fund, Logos Capital, Alexandria Real Estate Equities.